Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Rouanne, Mathieu ^a,b,c,d   Adam, Julien ^a,b   Goubar, Aïcha ^a   Robin, Angélique ^a   Ohana, Caroline ^c   Louvet, Emilie ^a   Cormier, Jiemin ^a   Mercier, Olaf ^b,e,f   Dorfmüller, Peter ^e,f   Fattal, Soly ^e   de Montpreville, Vincent Thomas ^e,f   Lebret, Thierry ^d   Dartevelle, Philippe ^b,e,f   Fadel, Elie ^b,e,f   Besse, Benjamin ^a,f,g   Olaussen, Ken André ^a,b,f   Auclair, Christian ^b,c   Soria, Jean Charles ^a,b,f,g  

^a Universite Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Ecole Normale Superieure de Cachan   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^f Institut d' Oncologie Thoracique   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Circulating biomarker; Non small cell lung cancer; Osteopontin; Thrombospondin 1; Tumor microenvironment

Indexed keywords

OSTEOPONTIN; THROMBOSPONDIN 1; SPP1 PROTEIN, HUMAN; THROMBOSPONDIN-1, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG LOBECTOMY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; WEDGE RESECTION; BLOOD; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOSPONDIN 1;

EID: 84978287533     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2541-5     Document Type: Article

References (45)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-9.
3. Demicheli R, Fornili M, Ambrogi F, et al. Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases. J Thorac Oncol. 2012;7:723-30.
4. The NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375:1267-77.
5. Friboulet L, Olaussen KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368(12):1101-10.
6. Wong GS, Rustgi K. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. Br J Cancer. 2013;108(4):755-61.
7. Swartz MA, Iida N, Roberts EW, et al. Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy. Cancer Res. 2012;72:2473-80.
8. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309-22.
9. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563-72.
10. Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev. 2010;29:295-307.
11. Bellahcène A, Castronovo V, Ogbureke KU, et al. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer. 2008;8(3):212-26.
12. Roberts DD. Thrombospondins: from structure to therapeutics. Cell Mol Life Sci. 2008;65(5):699-71.
13. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med. 2002;6:1-12.
14. Yee KO, Streit M, Hawighorst T, et al. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol. 2004;165(2):541-52.
15. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci. 2008;65:700-12.
16. Martin-Manso G, Galli S, Ridnour LA, et al. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res. 2008;68:7090-9.
17. Young MF, Kerr JM, Termine JD, et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics. 1990;7:491-502.
18. Anborgh PH, Mutrie JC, Tuck AB, et al. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal. 2011;5:111-22.
19. Anborgh PH, Mutrie JC, Tuck AB. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14:2037-44.
20. El-Tanani MK. Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosc. 2008;13:4276-84.
21. Fedarko NS, Jain A, Karadag A, et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001;7:4060-6.
22. Rud AK, Boye K, Øijordsbakken M. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer. 2013;13:540.
23. Ostheimer C, Bache M, Güttler A, et al. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer. 2014;14:858.
24. Ahmed M, Behera R, Chakraborty G, et al. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets. 2011;15(9):1113-26.
25. Isa S, Kawaguchi T, Teramukai S, et al. Serum osteopontin levels are highly prognostic for survival in advanced non-small-cell lung cancer: Results from JMTO LC 0004. J Thorac Oncol. 2009;4:1104-10.
26. Blasberg JD, Pass HI, Goparaju CM, et al. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol. 2010;28(6):936-41.
27. Travis WD, Brambilla E, Muller-Hermlink HK, et al. Pathology and genetics of tumours of the lung, pleura, thymus and heart. In: World Health Organization classification of tumours. Lyon: IARC Press; 2004.
28. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-85.
29. Goldstraw P, Crowley J, Chansky K. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706-14.
30. Pailler E, Adam J, Barthélémy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2013;31(18):2273-81.
31. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. http://www.rproject.org
32. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9:285-93.
33. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559-64.
34. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010;103:861-9.
35. Hu Z, Lin D, Yuan J, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res. 2005;11:4646-52.
36. Donati V, Boldrini L, Dell'Omodarme M, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res. 2005;11:6459-65.
37. Le QT, Sutphin PD, Raychaudhuri S, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9:59-67.
38. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis- associated protein osteopontin in human breast cancer. Cancer Res. 2002;62:3417-27.
39. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94:513-21.
40. Mack PC, Redman MW, Chansky K, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008;26:4771-6.
41. Takenaka M, Hanagiri T, Shinohara S, et al. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer. 2013;14(3):288-94.
42. Yamaguchi M, Sugio K, Ondo K, et al. Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer. 2002;36(2):143-50.
43. Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst. 1997;89(3):219-27.
44. Zabrenetzky V, Harris CC, Steeg PS, et al. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer. 1994;59:191-5.
45. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, meta- static potential, and angiogenesis. Cancer Res. 1994;54:6504-11.